Amedisys

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amedisys reports robust Q4 earnings, eyes growth amidst operational challenges

Amedisys showcases strong financial performance and strategic initiatives for 2023, focusing on growth and operational optimization.
Despite challenges like labor market issues and operational hurdles, the company remains confident in its growth strategies and talent management.
Opportunities in negotiations with payers, talent acquisition, and operational enhancements position Amedisys for continued success and revenue growth.
With a positive outlook for 2023 and a resilient approach to challenges, Amedisys is poised for steady growth and operational improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The High Acuity Care segment includes providing home care recovery for high acuity patients on either a full risk or limited risk basis. The company was founded in 1982 and is headquartered in Baton Rouge, LA.

Addus HomeCare

Bluerock Residential Growth REIT

NRG Energy

AquaVenture Holdings

Fed was compelled to reduce it in three consecutive and equal tranches of 25 basis points to sustain the expansion of the U.S. economy.

5 Top Stocks to Gain From Fed's Stable Monetary Stance

Amedisys, Inc. (AMED) CEO Paul Kusserow on Q3 2019 Results - Earnings Call Transcript

Hint: Adjusted earnings numbers can involve plenty of adjustments.

How Amedisys Blew Past Q3 Earnings Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 27.78% and 0.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Amedisys (AMED) Beats Q3 Earnings and Revenue Estimates

BATON ROUGE, La., Oct.  29, 2019  (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2019.

Amedisys Reports Third Quarter 2019 Financial Results and Updates 2019 Guidance

BATON ROUGE, La., Oct.  23, 2019  (GLOBE NEWSWIRE) -- Amedisys Inc. (NASDAQ:AMED), a leading independent home health, hospice and personal care company, announced today that after more than 15 years of distinguished service and leadership, including five years as Chairman, Donald A. Washburn is retiring as Chairman of the Board and will not seek reelection at the 2020 Annual Meeting. The Board unanimously elected President and Chief Executive Officer, Paul Kusserow, as the Chairman of the Board and Richard A. Lechleiter as Lead Independent Director, effective immediately.

Amedisys Announces Retirement of Donald A. Washburn and Welcomes Three New Directors

GATX

HCA Healthcare

Skechers U.S.A.

Stamps.com

Interest coverage ratio is used to determine how effectively a company can pay the interest charged on its debt.

Add These 5 Stocks With Amazing Interest Coverage Ratio

Most of Any Home Health and Hospice Organization in 2019 Most of Any Home Health and Hospice Organization in 2019

Amedisys Wins 18 Aster Awards for Home Health and Hospice Marketing

BATON ROUGE, La., Oct.  03, 2019  (GLOBE NEWSWIRE) -- Strategic Healthcare Programs (SHP) recently honored 111 Amedisys, Inc. (NASDAQ:AMED) care centers with SHPBest Awards, recognizing agencies with consistently high-quality care.

SHP Honors 111 Amedisys Care Centers with SHPBest Awards

Amedisys (AMED) is currently enjoying investors' confidence, thanks to solid prospects.

Here's Why You Should Invest in Amedisys (AMED) Right Now

Chemed

LHC Group

Outlook for Outpatient and Home Healthcare Industry Looks Bright

Amedisys, Inc. (AMED) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Amedisys

CFO of Amedisys Inc (30-Year Financial, Insider Trades) Scott G Ginn (insider trades) sold 4,871 shares of AMED on 08/05/2019 at an average price of $132.06 a share.

Amedisys Inc (AMED) CFO Scott G Ginn Sold $643,264 of Shares

Amedisys' (AMED) CEO Paul Kusserow on Q2 2019 Results - Earnings Call Transcript

Here's what you need to know about the home health and hospice provider's Q2 earnings results.

Amedisys Q2 Earnings: By the Numbers and Behind the Numbers

Robust year-over-year growth in Medicare and non-Medicare revenues aids Amedisys' (AMED) Home Health and Hospice divisions.

Amedisys (AMED) Q2 Earnings Top Estimates, Margins Decline

Amedisys (AMED) delivered earnings and revenue surprises of 24.74% and 0.40%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Amedisys (AMED) Q2 Earnings and Revenues Surpass Estimates

Charles River Laboratories

Humana

PRA Health Sciences

Teladoc

Healthcare stocks like HUM, AMED, CRL, TDOC and PRAH are likely to benefit from higher membership and revenues in the second quarter.

Healthcare Stock Q2 Earnings Due on Jul 31: HUM, AMED & More

Holly Energy Partners

M.D.C. Holdings

SkyWest

Mid-cap stocks have rallied in 2019. These stocks can become very useful in a volatile trading scenario.

5 Must-Buy Mid-Cap Stocks Ahead of Q2 Earnings This Week

Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amedisys (AMED) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

AbbVie

Genesco

Laureate Education

Cross the age-old barrier of low P/E investing, bet on these five stocks that boast rising P/E.

Use Rising P/E Strategy to Buy 5 Winning Stocks

Within Home Health, Amedisys (AMED) is expected to boost same-store volumes in Q2 via higher admissions and re-certifications.

Can Home Health Growth Support Amedisys' (AMED) Q2 Earnings?

Amedisys' (AMED) recently-integrated Personal Care segment is attaining stability and living up to expectation.

Amedisys Rides on New Buyouts, Strength in Personal Care Arm

Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Amedisys (AMED) Upgraded to Strong Buy: Here's What You Should Know

Medifast

Marine Products

Shoe Carnival

Do you have more faith in DuPont analysis than a simple ROE calculation?  Bet on these five stocks then.

News for Amedisys Stock (AMED)